At the Head and Heart of Oxytocin's Stress-Regulatory Neural and Cardiac Effects: A Chronic Administration RCT in Children with Autism

What Was Tested

This randomized controlled trial paper looks at Oxytocin.

The researchers aimed to examine the impact of a 4-week course of intranasal oxytocin on amygdala functional connectivity in children with autism, compared to placebo.

Why It Was Studied

Previous investigations have emphasized the amygdala as the neural foundation for oxytocin's acute effects.

However, to fully understand oxytocin's therapeutic potential, it is crucial to gain insight into the neuroplastic changes in amygdala circuitry induced from chronic oxytocin administrations, particularly in pediatric populations.

Who Took Part

According to the abstract, 45 boys were involved.

By PubMed's age tags, the people studied were children, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Oxytocin could be set against what happens without it.

Resting-state fMRI scans and simultaneous, in-scanner heart rate recordings were obtained before, immediately after, and 4 weeks after the nasal spray administration period.

What Was Measured

PubMed files the paper under topics including Oxytocin, Autistic Disorder, Autism Spectrum Disorder, Receptors, Oxytocin, Amygdala and Magnetic Resonance Imaging.

Author keywords: Amygdala circuitry, Heart rate variability and fMRI neuroimaging.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin in 45 boys.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Psychotherapy and psychosomatics), a journal based in Switzerland.

More context: the Oxytocin compound page, all human trials.